Cargando…
Safety, pharmacokinetics and pharmacodynamics of SBT‐020 in patients with early stage Huntington's disease, a 2‐part study
AIMS: Huntington's disease (HD) is a neurodegenerative disease with cognitive, motor and psychiatric symptoms. Toxic accumulation of misfolded mutant huntingtin protein induces mitochondrial dysfunction, leading to a bioenergetic insufficiency in neuronal and muscle cells. We evaluated the safe...
Autores principales: | van Diemen, Marcus P.J., Hart, Ellen P., Abbruscato, Anthony, Mead, Liz, van Beelen, Ilse, Bergheanu, Sandrin C., Hameeteman, Pieter W., Coppen, Emma, Winder, Jessica Y., Moerland, Matthijs, Kan, Hermien, van der Grond, Jeroen, Webb, Andrew, Roos, Raymund A.C., Groeneveld, Geert Jan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247328/ https://www.ncbi.nlm.nih.gov/pubmed/33197078 http://dx.doi.org/10.1111/bcp.14656 |
Ejemplares similares
-
Atrophy of the putamen at time of clinical motor onset in Huntington’s disease: a 6-year follow-up study
por: Coppen, Emma M., et al.
Publicado: (2018) -
Structural and functional changes of the visual cortex in early Huntington's disease
por: Coppen, Emma M., et al.
Publicado: (2018) -
Early grey matter changes in structural covariance networks in Huntington's disease
por: Coppen, Emma M., et al.
Publicado: (2016) -
Current Pharmacological Approaches to Reduce Chorea in Huntington’s Disease
por: Coppen, Emma M., et al.
Publicado: (2016) -
Exploratory 7-Tesla magnetic resonance spectroscopy in Huntington’s disease provides in vivo evidence for impaired energy metabolism
por: van den Bogaard, Simon J. A., et al.
Publicado: (2011)